AU2024259993A1 - Cdk2 inhibitors and methods of using same - Google Patents

Cdk2 inhibitors and methods of using same

Info

Publication number
AU2024259993A1
AU2024259993A1 AU2024259993A AU2024259993A AU2024259993A1 AU 2024259993 A1 AU2024259993 A1 AU 2024259993A1 AU 2024259993 A AU2024259993 A AU 2024259993A AU 2024259993 A AU2024259993 A AU 2024259993A AU 2024259993 A1 AU2024259993 A1 AU 2024259993A1
Authority
AU
Australia
Prior art keywords
heterocyclyl
cycloalkyl
compound
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024259993A
Other languages
English (en)
Inventor
Chang Bai
Yexing CAO
Jialiang QIN
Jing Su
Hongjian YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Touchstone Translational Research Institute Co Ltd
Foshan Ionova Biotherapeutics Co Inc
Shenzhen Ionova Life Science Co Ltd
Original Assignee
Guangdong Touchstone Translational Research Institute Co Ltd
Foshan Ionova Biotherapeutics Co Inc
Shenzhen Ionova Life Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Touchstone Translational Research Institute Co Ltd, Foshan Ionova Biotherapeutics Co Inc, Shenzhen Ionova Life Science Co Ltd filed Critical Guangdong Touchstone Translational Research Institute Co Ltd
Publication of AU2024259993A1 publication Critical patent/AU2024259993A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
AU2024259993A 2023-04-24 2024-04-23 Cdk2 inhibitors and methods of using same Pending AU2024259993A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2023090329 2023-04-24
CNPCT/CN2023/090329 2023-04-24
US202363501034P 2023-05-09 2023-05-09
US63/501,034 2023-05-09
CNPCT/CN2023/127659 2023-10-30
CN2023127659 2023-10-30
US202363615863P 2023-12-29 2023-12-29
US63/615,863 2023-12-29
PCT/CN2024/089320 WO2024222678A1 (fr) 2023-04-24 2024-04-23 Inhibiteurs de cdk2 et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
AU2024259993A1 true AU2024259993A1 (en) 2025-11-06

Family

ID=93255543

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024259993A Pending AU2024259993A1 (en) 2023-04-24 2024-04-23 Cdk2 inhibitors and methods of using same

Country Status (6)

Country Link
EP (1) EP4702015A1 (fr)
KR (1) KR20260039645A (fr)
CN (1) CN121443596A (fr)
AU (1) AU2024259993A1 (fr)
IL (1) IL324169A (fr)
WO (1) WO2024222678A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
PL3060562T3 (pl) * 2013-10-21 2022-01-10 Genosco Podstawione związki pirymidynowe i ich zastosowanie jako inhibitory syk
WO2018226739A1 (fr) * 2017-06-06 2018-12-13 Signalrx Pharmaceuticals, Inc. Thiénopyranones et furanopyranones à titre d'inhibiteurs de point de contrôle et de modulateurs de l'immunité antitumorale
US20210101881A1 (en) * 2018-02-12 2021-04-08 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Pyrimidine compound, preparation method thereof and medical use thereof

Also Published As

Publication number Publication date
WO2024222678A1 (fr) 2024-10-31
CN121443596A (zh) 2026-01-30
IL324169A (en) 2025-12-01
KR20260039645A (ko) 2026-03-20
EP4702015A1 (fr) 2026-03-04

Similar Documents

Publication Publication Date Title
CN110724143B (zh) 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用
AU2012204982B2 (en) 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors
KR102662358B1 (ko) Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
TWI551595B (zh) 2,4-disubstituted benzene-1,5-diamine derivatives and their use, Its preparation of pharmaceutical compositions and pharmaceutical compositions
JP2019522055A (ja) Fgfr阻害剤として使用される複素環式化合物
JP2013535491A (ja) フタラジノンケトン誘導体、その製造法および医薬用途
TW202024037A (zh) 用於治療特定白血病之化合物
KR20150126391A (ko) 신규 피리미딘 및 피리딘 화합물 및 이들의 용도
EP3380475A1 (fr) Dérivés d&#39;octahydropyrrolo [3, 4-c
AU2024245104A1 (en) Compound acting as wrn helicase inhibitor
CA3015166C (fr) Composes 6,7-dihydro-5 h-pyrazolo [5,1-b] [1,3]oxazine-2-carboxamide
WO2021099832A2 (fr) Composés antagonistes des récepteurs de l&#39;adénosine
WO2015066697A1 (fr) Morpholinopyrimidines fusionnées et procédés d&#39;utilisation de ces dernières
CA3231988A1 (fr) Compose macrocycle azaindazole et son utilisation
EP4702015A1 (fr) Inhibiteurs de cdk2 et leurs procédés d&#39;utilisation
WO2011082271A2 (fr) Composés triazolo-pyrimidine substitués
TWI894448B (zh) Ctla-4小分子降解劑及其應用
JP6977038B2 (ja) Gsk−3阻害剤
CN114075196B (zh) 一类芳香环并内酰胺类化合物、其制备方法和用途
CA3223874A1 (fr) Composes de pyrimidine destines a etre utilises en tant qu&#39;inhibiteurs de map4k1
WO2024067820A1 (fr) Composés tricycliques en tant qu&#39;inhibiteurs de cdk et leurs procédés d&#39;utilisation
TW202604908A (zh) 雜環化合物及其作為ret抑制劑的用途
WO2023033740A1 (fr) Composés utiles dans la modulation de la signalisation ahr
EP4698531A1 (fr) Composés de pyrrolopyrazine, leur préparation et leurs utilisations thérapeutiques
FR3025200A1 (fr) Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques